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Background. Colorectal cancer (CRC) is the second deadliest malignancy worldwide. This study aimed to compare the diagnostic
accuracy of different fecal markers in the detection of colorectal adenomas and cancer. Methods. Stool samples of patients
referred to colonoscopy were collected for the analysis of tumor M
2
pyruvate kinase (M
2
PK), human hemoglobin (Hb),
hemoglobin/haptoglobin (Hb/Hp) complex, fecal calprotectin (FC), and matrix metalloproteinase-9 (MMP-9). Results. Sensitivity
and specificity of M
2
PK for adenomas sized > 1 cm were 60% and 67.5% and for CRC were 94.7% and 67.5%. Sensitivity and
specificity of iFOBT for adenomas sized ≥ 1 cm were 80% and 72.5% and for CRC were 94.7% and 72.5%. Sensitivity and specificity
of Hb/Hp complex for adenomas sized≥ 1 cmwere 80% and 52.9% and for CRCwere 100% and 52.9%. Sensitivity of FC andMMP-9
for CRC was 77.8% and 72.2%. Combined use of M
2
PK, iFOBT, and FC resulted in a sensitivity and specificity of 95% and 47.5% for
the detection of adenomas sized ≥ 1 cm. Discussion. In CRC, sensitivity of M
2
PK, iFOBT, and Hb/Hp complex proved to be high.
Combined use of M
2
PK, iFOBT, and FC may be valuable in the detection of large adenomas.
1. Introduction
Colorectal cancer (CRC) incidence and mortality rates vary
markedly worldwide. Globally, CRC is a third most common
cancer, being a significant leading cause of cancer death
in both genders [1]. Furthermore, the incidence of CRC is
increasing in Central European countries [1]. The Hungarian
mortality rates for CRC proved to be the highest among men
in Europe in 2012 [2].
The vast majority of CRC cases are sporadic colon
cancers characterized by amultistep carcinogenic process [3].
Advanced adenomas greater than 10mm in diameter with
high-grade dysplasia or with more than 20% villous compo-
nent are considered to be the clinically relevant precursors
of CRC. However, the long premalignant phase of sporadic
CRCs provides a good opportunity for successful screening
and intervention.
Colonoscopy is considered the gold standard of CRC
screening tools. However,mainly due to the invasive nature of
colonoscopy, the acceptance of this type of screening method
among patients is low. The most commonly used noninva-
sive screening method for CRC is the guaiac fecal occult
blood test (gFOBT) based on the detection of hemoglobin
peroxidase activity in the stool. However, the sensitivity and
the specificity of this test are not good enough to safely
rule out the presence of CRC or adenomas which is why
there is a great need for a better noninvasive marker for
these conditions. In the case of proximal malignant lesions,
hemoglobin/haptoglobin (Hb/Hp) detection can be superior
to Hb detection alone since Hb/Hp complex remains stable
over the entire course of the large bowel in comparison to
Hb degraded on the way [4–6]. M
2
pyruvate kinase (PK)
is a biochemical form of PK which is a key enzyme in
cancer cell metabolism [7]. M
2
PK is expressed in normal
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proliferating cells, embryonic cells, adult stem cells, and
cancer cells [8]. Elevated levels of M
2
PK have been detected
in colonic adenocarcinoma [9]. Calprotectin is a calcium-
binding and zinc-binding protein complex that is abundant
in the cytosol of inflammatory cells [10, 11]. Fecal calprotectin
(FC), a biomarker of intestinal inflammation, has been in
clinical use for years in inflammatory bowel disease [11–13].
FC has been shown to be elevated in CRC and has been
suggested to be for screening high risk groups for CRC [14].
Matrix metalloproteinase (MMP) is a large family of
calcium-dependent zinc-containing endopeptidases respon-
sible for tissue remodelling and degradation of the extracellu-
lar matrix components, including collagens, elastins, gelatin,
matrix glycoproteins, and proteoglycan, in multiple disease
settings including malignant processes. MMP-9 subtypes
are believed to play a crucial role in the progression and
metastasis formation of many tumors, including CRC [15].
Since the majority of the abovementioned tests are not
officially recommended in the CRC screening guidelines and
some of them have not been tested previously, the aim of
this study was to compare the diagnostic accuracy of different
fecal markers in the detection of precancerous and cancerous
lesions of the colorectum and to find the most accurate for
CRC screening.
2. Methods
2.1. Patient Population and Study Protocol. Patients from the
1st Department of Medicine, University of Szeged, who were
referred for colonoscopy were invited to participate in the
study. Data on symptoms, smoking habits, family history,
and current medication were collected. Every patient was
informed about the study details and asked to sign written
consent. The patients were instructed for sample collection
and handling. All patients were asked to collect stool samples
one day before administration of bowel preparation. Plastic
containers were provided for feces collection. After bringing
the samples at the lab of the clinic, they were frozen at −20∘C
until further analysis. Patients did not have to keep a special
diet andwere told to take their usualmedications. Selection of
the patient groups with adenomas sized <1 cm and ≥1 cm and
CRC was based on the endoscopic and histological finding.
The stool testing for M
2
PK, iFOBT, FC, and MMP-9 was
carried out by a single trained person who was blinded to the
results of the colonoscopy.
The study was approved by the Regional and Institutional
HumanMedical Biological Research Ethics Committee of the
University of Szeged.
2.2. Measurement of Fecal M2PK and iFOBT. A combined
rapid immunochromatographic lateral flow test was used
for simultaneous detection of enzyme biomarker M
2
PK
and human hemoglobin (combined M
2
PK and HB, 2 in 1
Quick Test, ScheBo Biotech). For these measurements, stool
samples were thawed and a special stick capturing 4mg of
stool was loaded. These tests are based on visual inspection
of colors at test and control lines. The result is exclusively
qualitative (detection limit of M
2
PK was 4U/mL; detection
limit of Hb was 15 ng/mL).
2.3. Measurement of Fecal Hb and Hb/Hp Complex. Hb/Hp
complex was determined from stool samples with a visual
immunochromatographic quick test: ColonView Hb and
Hb/Hp fecal occult blood test (Biohit HealthCare; detection
limit of Hb was 15 ng/mL; detection limit of Hb/Hp was
4 ng/mL).
2.4. Measurement of FC and Fecal MMP-9. For FC mea-
surements, fecal specimens were thawed at 4∘C. FC level
was quantified by using enzyme-linked immunosorbent
assay (Quantum Blue, BU¨HLMANN Laboratories Ltd.,
Scho¨nenbuch) according to the manufacturer’s instructions.
For MMP-9 measurements, 1 g of fecal samples was diluted,
mixed, homogenised in 4mL of ice-cold Tris-buffer (0.15M
NaCl + 20mM Tris-HCl, pH 8.3), and then centrifuged.
MMP-9 was also measured by quantitative enzyme-linked
immunosorbent assay (R&D Systems, Abingdon, UK) [16].
2.5. Colonoscopy and Histological Examination. Diagnosis
was based on the endoscopic and histopathological find-
ings. Colonoscopies were performed by three experienced
endoscopists (TM, ZSZ, and FN) who were blinded to fecal
tests results. Carcinomas were classified according to the
Dukes staging system and location. Adenomatous polyps
were classified according to histopathological characteristics,
size (large polyps: ≥1 cm; small polyps: <1 cm), and location.
All colonoscopy biopsies were examined by an expert pathol-
ogist (LT). The diagnoses were reported using the standard
WHO classification of colorectal neoplasia. In addition to
their size, all polypoid lesions were classified as hyperplastic
polyps or adenomas, being further classified according to
their histological pattern as tubular, tubulovillous, villous, or
serrate adenomas.
2.6. Statistical Analysis. CRCs and adenomas were analysed
separately.The diagnostic value of fecal markers for detecting
adenomas and CRCs was assessed by calculating the sensi-
tivity and the specificity of the test. Correlations between FC
and MMP-9 and endoscopic findings were determined by
ANOVAmethod.The cut-off levels, specificity, and sensitivity
between CRC and control groups were calculated using the
receiver operating characteristic (ROC) analysis. All statis-
tical analyses were carried out using STATA 9 (StataCorp,
TX, 2005). P values < 0.05 were considered to be statistically
significant.
3. Results
3.1. Patient Population. Ninety-five consecutive in- and out-
patients admitted for total colonoscopy between September
2014 and April 2015 were prospectively enrolled in the study.
Indications for colonoscopies were abdominal complaints,
bloody stool, family history of CRC, and prior colorectal
adenoma. Patients with active gastrointestinal bleeding,men-
struation, and past history of total colectomy were excluded
from the study. Study groups were defined on the basis of the
result of colonoscopy and histological evaluation.
Mean age was 67 years (range: 21–92) in study population.
57 female and 38 male patients were in these three groups,
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Table 1: Demographic characteristics of the study population.
Demographic data All patients (95) Control group (40) Adenoma group (36) Cancer group (19)
Female/male 38/57 19/21 14/22 5/14
Age (years) 67 (21–92) 67 (21–87) 68 (51–81) 65 (44–92)
Current smokers 13 (13.7%) 4 (10%) 5 (13.9) 4 (21.1)
Comorbidities
Hypertension 54 (56.8%) 23 (57.5%) 22 (61.1%) 9 (47.4%)
Diabetes mellitus 21 (22.1%) 7 (17.5%) 8 (22.2%) 6 (31.6%)
Hyperlipidaemia/hypercholesterinemia 22 (23.2%) 9 (22.5%) 11 (30.6%) 2 (10.5%)
Cardiovascular disease 25 (26.3%) 11 (27.5%) 10 (27.7%) 4 (21.1%)
Cerebrovascular disease 13 (13.7%) 6 (15%) 4 (11.2%) 3 (15.8%)
Hyper/hypothyroidism 13 (13.7%) 5 (12.5%) 7 (19.4%) 1 (5.3%)
Pulmonary disease 6 (6.3%) 4 (10%) 2 (5.6%) 0
Gout 11 (11.6%) 5 (12.5%) 5 (13.9%) 3 (15.8%)
Autoimmune disease 4 (4.2%) 0 3 (8.3%) 1 (5.3%)
Malignant disease (simultaneously) 3 (3.2%) 1 (2.5%) 2 (5.6%) 0
Hepatitis (B, C) 2 (2.1%) 1 (2.5%) 1 (2.8%) 0
Diverticulum 24 (25.3%) 11 (27.5%) 10 (27.8%) 3 (15.8%)
Haemorrhoids 20 (21.1%) 11 (27.5%) 7 (19.4%) 2 (10.5%)
respectively. Demographic characteristics of the study pop-
ulation are summarized in Table 1. Family history of CRC
was reported by 26 patients. Considering therapy, 26 patients
received aspirin or clopidogrel and 4 received acenocoumarol
or heparin at the time of the investigation.
3.2. Colonoscopic and Histological Findings. Forty of the
95 patients included in the study represented the control
group without any premalignant or malignant findings on
endoscopy. Nine of the control patients presented with initial
diverticulosis without any sign of inflammation. Colono-
scopic findings in the remaining patients of the control group
were totally normal.
Thirty-six patients were diagnosed with adenomas (ade-
noma group). In the adenoma group, 16 patients presented
with adenomas sized <1 cm and 20 with adenomas sized
≥1 cm. Adenomas sized <1 cm were equally located at the
proximal and the distal part of the colon. The location
of adenomas sized ≥1 cm in the majority (65%) of the
patients was the proximal part of the colon. In twenty-three
adenomatous cases, a histologic sample was obtained. In the
remaining thirteen cases, the samples were less than 1 cm and
did not suggest the presence of malignancy. Based on the
histological assessment of the samples (𝑛 = 23), in 78.3%
of the cases (in 18 patients), the adenomas were with low-
grade dysplasia; in 13% (in 3 patients), adenomas were with
high-grade dysplasia; and in 8.7% (in 2 patients) there were
hyperplastic polyps. In 56.5% of the patients the adenomas
were of the tubular type, in 4.3% they were of the villous type,
and in 30.4% they belong to the tubulovillous type.
Cancer was found in 19 cases, and, according to their
histological evaluation, the tumors were identified as adeno-
carcinomas. In 89% of the patients, the cancer was located in
the distal colon (in 10 patients in the rectum and in 7 patients
in the sigmoid colon). In the remaining 2 cases, the tumor
was located in the distal part of the transverse colon. 28.8% of
Table 2: The numbers of patients having different stages of cancer
according to Dukes classification.
Dukes stage Patients
Carcinoma in situ 1
Dukes A 3
Dukes B 9
Dukes C 1
Dukes D 5
these patients had a family history of CRC. The numbers of
patients having different stages of cancer according to Dukes
classification are shown in Table 2.
3.3. Diagnostic Accuracy of Fecal Markers in Adenomas and
CRCs. M
2
PK was positive in 32.5% of the patients with
normal colonoscopy, in 43.7% with adenomas sized <1 cm, in
60% with adenomas sized ≥1 cm, and in 94.7% with CRCs.
M
2
PK sensitivity for adenomas sized >1 cm was 60%, and
specificity was 67.5%. Sensitivity and specificity for CRCwere
94.7% and 67.5%. Sensitivity and specificity for iFOBT for
adenomas sized≥1 cmwere 80% and 72.5% and for CRCwere
94.7% and 72.5%. The Hb/Hp (Hb and Hb/Hp ColonView
Biohit test) complex was positive in 47.1% of the patients
with normal colonoscopy, in 50% with hyperplastic polyps,
in 54% with adenomas sized <1 cm, in 80% with adenomas
sized≥1 cm, and in 100%with CRC. Sensitivity and specificity
of Hb/Hp complex for adenomas sized ≥1 cm were 80% and
52.9% and for CRC were 100% and 52.9%.
FC andMMP-9 differed significantly between the control
and CRC group (𝑝 = 0.022; 𝑝 < 0.001); however, no differ-
ence was found in FC and MMP-9 concentrations between
the control and the adenoma groups. FC was significantly
lower in adenomas sized<1 cm compared toCRCs but did not
differ when compared to adenomas sized ≥1 cm with CRCs
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Table 3: Sensitivities, specificities, and positive and negative predictive values of the fecal markers.
Parameters M
2
-PKScheBo HBSchBo HB/HPbiohit Calprotectin MMP-9
Sensitivity
Adenoma sized ≥1 cm 60 80 80.0
CRC 94.7 94.7 100.0 77.8 72.2
Adenoma sized ≥1 cm + CRC 76.9 87.2 90.9
Specificity
Adenoma sized ≥1 cm 67.5 72.5 52.9
CRC 67.5 72.5 52.9 70.0 95.0
Adenoma sized ≥1 cm + CRC 67.5 72.5 52.9
PPV (%)
Adenoma sized ≥1 cm 80 59.2 42.9
CRC 85.7 62 52.9 53.8 86.6
Adenoma sized ≥1 cm + CRC 69.7 75.5 65.2
NPV (%)
Adenoma sized ≥1 cm 77.1 96.6 85.7
CRC 96.4 96.6 100.0 87.5 88.3
Adenoma sized ≥1 cm + CRC 75 85.3 85.7
(𝑝 = 0.022, 𝑝 = 0.089). MMP-9 proved to be significantly
lower compared to either adenomas sized<1 cmwithCRCs or
adenomas sized ≥1 cm with CRCs (𝑝 ≤ 0.001 and 𝑝 ≤ 0.001).
Sensitivity of FC for CRC was 77.8%, while specificity for
CRC was 70%. The cut-off value of FC for the detection of
CRC was 128.5 𝜇g/g (AUC = 0.77, 𝑝 = 0.001). Sensitivity of
MMP-9 for CRC was 72.2%, while specificity was 95%. The
cut-off value ofMMP-9 for the detection of CRCwas 1.12 ng/g
(AUC = 0.77, 𝑝 < 0.001).
Using combinations of fecal markers, the highest sensi-
tivity for detection of adenomas sized ≥1 cm was revealed
when combining M
2
PK, iFOBT, and FC (with the cut-off of
128.5𝜇g/g) resulting in a sensitivity and specificity of 95% and
47.5% for the detection of adenomas sized ≥1 cm.
Sensitivities, specificities, and positive and negative pre-
dictive values of the fecal markers are summarized in Table 3.
We did not find any relationship between platelet aggre-
gation inhibitor therapy and positive results of the different
hemoglobin tests (logistic regression: HbScheBo 𝑝 = 0.4;
Hb/HpBiohit 𝑝 = 0.609).
4. Discussion
CRC is a major health problem worldwide. Despite being a
good candidate for screening due to its detectable premalig-
nant lesions, mortality rates of CRC are still significant in
Hungary [17]. Early detection by an accurate, noninvasive,
cost-effective, simple-to-use screening technique is central to
decrease the incidence and mortality of this disease. Patient
discomfort, invasiveness, embarrassment, high cost, and con-
siderable expertise and equipment required for the procedure
may all limit the appeal of this screening technique and the
increasing number of examinations puts a huge burden on
the gastroenterologists. Thus, there is still an unmet need for
suitable noninvasive biomarkers to screen for CRC.
In this prospective colonoscopy-controlled study, we
assessed the sensitivity, specificity, and positive and negative
predictive values of different noninvasive fecal markers for
the detection of adenomas and CRC. For adenomas sized
≥1 cm, iFOBT showed the highest sensitivity and M
2
PK the
highest specificity. For CRC, M
2
PK and Hb/Hp complex
showed the highest sensitivity and fecal MMP-9 the highest
specificity. FC and fecal MMP-9 concentrations did not differ
between the control and the adenoma group, although they
proved to be beneficial mainly in the detection of adenomas
sized ≥1 cm and CRC. In CRCs, the sensitivities of FC and
MMP-9were 78% and 72%, with specificities of 70% and 95%.
The combination of M
2
PK, iFOBT, and FC increased their
sensitivity for the detection of adenomas sized ≥1 cm up to
95%.
The study has some limitations. First, we collected
stool samples before performing colonoscopy; thus, we were
blinded to the findings and the number of high-grade adeno-
mas finally proved to be low. We do not know whether there
would be associations between adenomas and fecalmarkers if
the number of adenomas with high-grade dysplasia would be
higher. Second, M
2
PK and Hb tests and the Hb/Hp complex
were all qualitative tests based on a chromatographic method
interpreted visually which may limit their assessment in case
of borderline results.Therefore, it may be difficult to compare
the results with those of FC andMMP-9. However, these tests
are simple, do not require specific laboratory equipment, and
therefore are less expensive than the quantitative methods.
The guaiac-based FOBT (gFOBT) is the oldest and most
commonly used noninvasive test for detecting CRC [18,
19]. Although the test is relatively inexpensive and easy to
perform, false-positive and false-negative results compose its
main limitation resulting in limited sensitivity for detecting
cancer and advanced adenomas [20]. The Hb/Hp complex
shows higher stability against degradation thanHb itself. Sieg
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et al. revealed thatHb/Hp complex has a comparable sensitiv-
ity to fecal Hb for CRCs (87% for both) and higher sensitivity
for adenomas (76% versus 54%) [4]. However, these tests are
based on the bleeding property of the adenomas. Since early-
stage cancers or advanced adenomas are unlikely to bleed
continuously, 100% of clinical sensitivity cannot be achieved
with the use of these tests. That is why the identification of
novel fecal-based biomarkers is important.
M
2
PK is expressed by proliferating cells, in particular
the tumor cells being direct target of several oncoproteins.
Among the first studies assessing the sensitivity of M
2
PK
for the detection of CRC, Shastri et al. revealed that fecal
M
2
PK assay had sensitivity and specificity of 81.1 and 71.1%
for diagnosing CRC at a cut-off value of 4U/mL whereas
FOBT showed a sensitivity of 36.5% and specificity of 92.2%
for CRC. They concluded that M
2
PK is a poor screening
biomarker, due to its low specificity [21]. However, a meta-
analysis including 17 studies performed between 2006 and
2010 found the mean fecal M
2
PK sensitivity and specificity
to be 80.3% and 95.2% for CRC and a sensitivity of 44% for
adenomas >1 cm [22].
According to our results, M
2
PK, Hb, and Hb/Hp tests
show better sensitivity in the detection of CRC than advanced
adenomas.The study byKim et al. revealed that the sensitivity
of iM
2
PK, an immunochromatographic qualitative method
for fecal M
2
PK for CRC, was 92.8% and for adenomatous
lesions the sensitivity was 69.4% [23]. Compared with M
2
PK
ELISA, iM
2
PK exhibited significantly enhanced sensitivity
for CRC (97.5% versus 80%, 𝑝 = 0.03).
FC is valuable in differentiating functional and organic
bowel diseases. FC was shown to be more sensitive (79%)
but less specific (72%) for CRC and adenomatous polyps as a
combined group than gFOBT [24]. MMP-9 is an important
member of the gelatinases involved in the development of
several human malignancies [25]. Yang et al. found that
MMP-9 expression in colon cancer tissues was significantly
higher than that in corresponding distal normal mucosa
tissue [15]. However, the sensitivity of MMP-9 detected in
feces has not been examined previously. Our results revealed
amoderate sensitivity of 72% and a good specificity of 95% for
fecal MMP-9 in CRC. However, neither FC nor fecal MMP-9
provided valuable information on the detection of adenomas.
In this study, we compared the sensitivity and specificity
of several fecalmarkers for the detection of colorectal cancers.
The strengths of this study are the design that allowed directly
calculating sensitivity and specificity of the different fecal
markers, since every patient underwent colonoscopy after
stool sample collection. This was the first time when five
biomarkers were simultaneously studied. Fecal M
2
PK has
the advantage that it detects both bleeding and nonbleeding
tumors and adenoma. Conversely, fecal M
2
PK does not have
false-positive results due to various noncancerous sources
of bleeding. Furthermore, FC, MMP-9, and fecal M
2
PK are
also sensitive to intestinal inflammation (inflammatory bowel
disease, diverticulitis) increasing the proportion of false-
positive cases. In this study, we performed examinations
for patients with GI symptom(s) not as a part of screening
process because by this method we could disclose false-
positive results and could determine specificity data as well.
In our cohort, the highest sensitivity and specificity were
achieved by the use of combined M
2
PK and iFOBT test in
the detection of CRC. FC seems to be a useful adjuvant to the
investigation of patients at high risk for colorectal neoplasia,
while fecal MMP-9 may be a promising factor for detection
of CRC. Although, in CRC, sensitivity of M
2
PK, iFOBT, and
Hb/Hp complex proved to be high, in adenomas sized ≥1 cm,
sensitivity decreased significantly. Therefore, none of these
markers are unique for detection of precancerous lesions of
the colorectum. However, our result revealed that combined
use ofM
2
PK, iFOBT, and FCmay be valuable in the detection
of large adenomas.
We recommend these noninvasive fecal tests in low-risk
patients and in patients who do not have comorbidities.
Results of FOBTmay be false positive if the source of bleeding
is not an adenoma or amalignant disease (diverticulitis, hem-
orrhoids, and anticoagulant therapy). However, inflamma-
tory diseases of the colon (diverticulitis, different infections,
and inflammatory bowel diseases) and extraintestinal cancer
(cancer in the hepatobiliary tract, pancreas) or inflammation
(hepatitis) may affect the results of the inflammatory marker
test; thus, in these cases, we recommend colonoscopy as a
one-step investigation. High-risk patients (who had at least
one relative with early CRC or adenoma or had at least two
relatives with CRC or adenoma) with symptoms or patients
who have early (under the age of 60) CRC or adenoma
among their relatives should also undergo colonoscopy.
However, it is not questionable whether continued efforts are
needed to discover effective tests to identify patients with
nonhereditary risk factors and to develop invasive and cost-
effective screening modalities.
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